Exosomal Nucleic Acid Delivery for Tumor Macrophage Repolarization

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing immunotherapies struggle to effectively repolarize tumor-associated macrophages from the cancer-promoting M2 phenotype to the anti-cancer M1 phenotype, leading to limited therapeutic efficacy due to lack of specificity and safety concerns from non-specific macrophage targeting.

Innovation Solution

Extracellular vesicles, such as exosomes, engineered with immunomodulating components like nucleic acids and antibodies, selectively repolarize macrophages from M2 to M1 phenotype by targeting specific genes and pathways, enhancing anti-tumor immune responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing immunotherapies are used to target macrophages, then macrophage polarization is attempted, but specificity is insufficient and safety concerns arise from non-specific targeting

Engineering Contradiction:

Improvespecificity of macrophage targetingVSAvoidnon-specific macrophage targeting effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses exosomes as intermediary carriers to deliver immunomodulating components (siRNA, antisense oligonucleotides, antibodies) specifically to tumor-associated macrophages. The exosomes act as a mediator that protects the therapeutic agents from degradation and enables targeted delivery to the desired cell population, thereby improving specificity while reducing non-specific effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs localized gene silencing and immunomodulation within the tumor microenvironment by delivering specific nucleic acid sequences and antibodies that act only on target genes (e.g., STAT3, C/EBPβ, Arginase-1) in tumor-associated macrophages. This localized action at the molecular and cellular level enhances specificity of the therapeutic effect

Inventive Principle:

Principle #3Local quality

2Productivity

If M2 macrophages are targeted for repolarization, then anti-cancer activity is enhanced, but therapeutic efficacy is limited by incomplete polarization

Engineering Contradiction:

Improveanti-tumor immune responseVSAvoidcompleteness of macrophage repolarization

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent combines multiple immunomodulating components (siRNA, antisense oligonucleotides, antibodies, and small molecules) within a single exosomal delivery system to simultaneously target multiple genes and pathways involved in macrophage polarization. This multi-component approach synergistically enhances the completeness and reliability of M2-to-M1 repolarization while maximizing anti-tumor immune response

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent employs sustained release of immunomodulating components from exosomes that persist in the tumor microenvironment, ensuring continuous suppression of M2-polarizing signals and promotion of M1 polarization. The exosomes provide ongoing therapeutic action that maintains complete repolarization over time rather than transient effects

Inventive Principle:

Principle #20Continuity of useful action

Data Source

PatentUS12570978B2Methods and compositions for macrophage polarization

Publication Date: 2026.03.10 LONZA SALES AG

AI summary

Disclosed herein are compositions and methods comprising extracellular vesicles comprising nucleic acid that target genes, leading to macrophage polarization of tumor associated macrophages. In certain embodiments, disclosed herein are methods and compositions for increasing macrophage polarization for the treatment of cancer.